CIITA-Dependent and -Independent Class II MHC Expression Revealed by a Dominant Negative Mutant

Journal of Immunology

Volumn 158, Issue 10, 1997, Pages 4741-4749

  Zhou, Hong ^a,b   Su, Henry S ^b   Zhang, Xiankui ^c   Douhan III, John ^a,b   Glimcher, Laurie H ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HLA D ANTIGEN; HLA DQ ANTIGEN; MHC CLASS II TRANSACTIVATOR PROTEIN; NUCLEAR PROTEIN; REPRESSOR PROTEIN; TRANSACTIVATOR PROTEIN;

ARTICLE; DOMINANT GENE; GENE; GENE DELETION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; PHYSIOLOGY; PROMOTER REGION; STRUCTURE ACTIVITY RELATION;

GENE EXPRESSION REGULATION; GENES, DOMINANT; GENES, MHC CLASS II; HLA-D ANTIGENS; HLA-DQ ANTIGENS; HUMANS; INTERFERON TYPE II; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); REPRESSOR PROTEINS; SEQUENCE DELETION; STRUCTURE-ACTIVITY RELATIONSHIP; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC;

EID: 0031569959     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Grusby, M. J., and L. H. Glimcher. 1995. Immune responses in MHC class II-deficient mice. Annu. Rev. Immunol. 13:417.
2. Mach, B., V. Steimle, and W. Reith. 1994. MHC class II-deficient combined immunodeficiency: a disease of gene regulation. Immunol. Rev. 138:207.
3. Mach, B., V. Steimle, E. Martinez-Soria, and W. Reith. 1996. Regulation of MHC class II genes: lessons from a disease. Annu. Rev. Immunol. 14:301.
4. Bottazzo, G. F., I. Todd, R. Mirakian, A. Belfiore, and R. Pujol-Borrell. 1986. Organ-specific autoimmunity: a 1986 review. Immunol. Rev. 94:137.
5. Glimcher, L. H., and C. J. Kara. 1992. Sequences and factors: a guide to MHC class-II transcription. Annu. Rev. Immunol. 10:13.
6. Benoist, C., and D. Mathis. 1990. Regulation of major histocompatibility complex class-II genes: X, Y and other letters of the alphabet. Annu. Rev. Immunol. 8:681.
7. Ting, J. P. Y., and A. S. Baldwin. 1993. Regulation of MHC gene expression. Curr. Opin. Immunol. 5:8.
8. Douhan, J., I. Hauber, M. M. Eibl, and L. H. Glimcher. 1996. Genetic evidence for a new type of major histocompatibility complex class II combined immunodeficiency characterized by a dyscoordinate regulation of HLA-D α and β chains. J. Exp. Med. 183:1063.
9. Reith, W., S. Satola, C. Herrero Sanchez, I. Amaldi, B. Lisowska-Grospierre, C. Griscelli, M. R. Hadam, and B. Mach. 1988. Congenital immunodeficiency with a regulatory defect in MHC class II gene expression lacks a specific HLA-DR promoter binding protein. RF-X. Cell 53:897.
10. Reith, W., C. Herrero Sanchez, M. Kobr, P. Silacci, C. Berte, E. Barras, S. Fey, and B. Mach. 1990. MHC class II regulatory factor RFX has a novel DNA-binding domain and a functionally independent dimerization domain. Genes Dev. 4:1528.
11. Steimle, V., B. Durand, E. Barras, M. Zufferey, M. R. Hadam, B. Mach, and W. Reith. 1995. A novel DNA binding regulatory factor is mutated in primary MHC class II-deficiency (bare lymphocyte syndrome). Genes Dev. 9:1021.
12. Steimle, V., L. A. Otten, M. Zufferey, and B. Mach. 1993. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 75:135.
13. Steimle, V., C. A. Siegrist, A. Mottet, B. Lisowska-Grospierre, and B. Mach. 1994. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 265:106.
14. Chin, K., C. Mao, C. Skinner, J. L. Riley, K. L. Wright, C. S. Moreno, G. R. Stark, J. M. Boss, and J. P. Y. Ting. 1994. Molecular analysis of G1B and G3A IFN-gamma mutants reveals that defects in CTITA or RFX result in defective class II MHC and Ii gene induction. Immunity 1:687.
15. Chang, C. H., J. D. Fontes, M. Peterlin, and R. A. Flavell. 1994. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II gene. J. Exp. Med. 180:1367.
16. Silacci, P., A. Mottet, V. Steimle, W. Reith, and B. Mach. 1994. Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA. J. Exp. Med. 180:1329.
17. Chang, C.-H., S.-C. Hong, C. C. W. Hughes, C. A. Janeway, Jr., and R. A. Flavell. 1995. CIITA activates the expression of MHC class II genes in mouse T cells. Int. Immunol. 7:1515.
18. Chang, C. H., and R. A. Flavell. 1995. Class II transactivator regulates the expression of multiple genes involved in antigen presentation. J. Exp. Med. 181: 765.
19. Ono, S. J., and Z. Song. 1995. Mapping of the interaction site of the defective transcription factor in the class II major histocompatibility complex mutant cell line clone-13 to the divergent X2-box. J. Biol. Chem. 270:6396.
20. Chang, C.-H., S. Guerder, S.-C. Hong, W. van Ewijk, and R. A. Flavell. 1996. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression. Immunity 4:167.
21. Zhou, H., and L. H. Glimcher. 1995. Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency. Immunity 2:545.
22. Sakurai, M., and J. L. Strominger. 1989. Studies of expression of the DQβ promoter and its 5′ deletion derivatives in normal and mutant human B cell lines. Tissue Antigens 34:64.
23. Zhou, H., and P. H. Duesberg. 1990. A retroviral promoter is sufficient to convert proto-src to a transforming gene that is distinct from the src gene of Rous sarcoma virus. Proc. Natl. Acad. Sci. USA 87:9128.
24. Kingston, R. E., J. Sheen, and D. Moore. 1989. Isotopic assays for reporter gene activity. In Current Protocols in Molecular Biology, Vol. I. Green Publishing Co., New York, p. 971.
25. Fuller, S. A., T. Miyoko, and J. G. R. Hurrell. 1989. Preparation of monoclonal antibodies. In Current Protocols in Molecular Biology, Vol. II. Green Publishing Co., New York, p. 1141.
26. Zhao, J-L., G. J. Freeman, G. S. Gray, L. M. Nadler, and L. H. Glimcher. 1996. A cell type specific enhancer in the human B7.1 gene regulated by NF-κB. J. Exp. Med. 183:777.
27. Mermod, N., E. A. O'Neill, T. J. Kelly, and R. Tijian. 1989. The proline-rich transcriptional activator of CTF/NF-1 is distinct from the replication and DNA binding domain. Cell 58:741.
28. Bours, V., G. Franzoso, V. Azarenko, S. Park, T. Kanno, K. Brown, and U. Siebenlist. 1993. The oncoprotein Bcl-3 directly transactivates through κB motifs via association with DNA-binding p50B homodimers. Cell 72:729.
29. Tanaka, M., and W. Herr. 1990. Differential transcriptional activation by Oct-1 and Oct-2: interdependent activation domains induce Oct-2 phosphorylation. Cell 60:375.
30. Hoey, T., R. O. J. Weinzierl, G. Gill, J.-L. Chen, B. D. Dynlacht, and R. Tijian. 1993. Molecular cloning and functional analysis of drosophila TAF110 reveal properties expected of coactivators. Cell 72:247.
31. Pongubala, J. M., S. Nagulapalli, M. J. Klemsz, S. R. McKercher, R. A. Maki, and M. L. Atchison. 1992. PU.1 recruits a second nuclear factor to a site important for immunoglobulin κ 3′ enhancer activity. Mol. Cell. Biol. 12:368.
32. Carman, J. A., and J. G. Monroe. 1995. The EGR1 protein contains a discrete transcriptional regulatory domain whose deletion results in a truncated protein that blocks EGR1-induced transcription. DNA Cell Biol. 14:581.
33. Manyak, C. L., H. Tse, P. Fischer, L. Coker, N. H. Sigal, and G. C. Koo. 1988. Regulation of class II MHC molecules on human endothelial cells: effects of IFN and dexamethasone. J. Immunol. 140:3817.
34. Ameglio, F., M. R. Capobianchi, A. Dolei, and R. Tosi. 1983. Differential effects of gamma interferon on expression of HLA class II molecules controlled by the DR and DC loci. Infect. Immun. 42:122.
35. Lucey, D. R., A. Nicholson-Weller, and P. F. Weller. 1989. Mature human eosinophils have the capacity to express HLA-DR. Proc. Natl. Acad. Sci. USA 86:1348.
36. Anichini, A., C. Castelli, G. Sozzi, G. Fossati, and G. Parmiani. 1988. Differential susceptibility to recombinant interferon-γ-induced HLA-DQ antigen modulation among clones from a human metastatic melanoma. J. Immunol. 140:183.
37. Symington, F. W., F. Levine, M. Braun, S. L. Brown, H. A. Erlich, and B. Torok-Storb. 1985. Differential Ia antigen expression by autologous human erythroid and B lymphoblastoid cell lines. J. Immunol. 135:1026.
38. Woodward, J. G., K. W. Omer, and P. M. Stuart. 1989. MHC class II transcription in different mouse cell types. J. Immunol. 142:4062.
39. Ono, S. J., V. Bazil, M. Sugawara, and J. L. Strominger. 1991. An isotype-specific transacting factor is defective in a mutant B cell line that expresses HLA-DQ, but not -DR or -DP. J. Exp. Med. 173:629.
40. Sherman, P. A., P. V. Basta, A. Heguy, M. K. Wloch, R. G. Roeder, and J. P. Y. Ting. 1989. The octamer motif is a B-lymphocyte-specific regulatory element of the HLA-DRα gene promoter. Proc. Natl. Acad. Sci. USA 86:6739.
41. Van Ewijk, W., Y. Ron, J. Monaco, J. Kappler, P. Marrack, M. Le Meur, P. Gerlinger, B. Durand, C. Benoist, and D. Mathis. 1988. Compartmentalization of MHC class II gene expression in transgenic mice. Cell 53:357.
42. d transgenic mice. Int. Immunol. 8:255.
43. Hasegawa, S. L., and J. M. Boss. 1991. Two B-cell factors bind the HLA-DRA X box region and recognize different subsets of HLA class II promoters. Nucleic Acids Res. 19:6269.